ReviewCurrent treatment options in infectious diseases2020
Hantavirus Infections-Treatment and Prevention.
Review in Current treatment options in infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The protective efficacy of inactivated vaccine against hemorrhagic fever with renal syndrome: A meta-analysis.Medicine · 2025Pooled it
- Hantavirus seroprevalence and associated factors for exposure in south-central Uganda.Emerging microbes & infections · 2026Article
- Hantavirus infections: A growing global health concern.World journal of virology · 2026Review
- A drug repurposing screen identifies antiviral compounds against Puumala Orthohantavirus.Scientific reports · 2026Article
- Human Orthohantavirus Infections: A Narrative Review.Pathogens (Basel, Switzerland) · 2026Review
- Hantavirus Disease: A Comprehensive Narrative Review of Epidemiology, Pathogenesis, Diagnosis, and Treatment.Cureus · 2026Review
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Hantavirus as a persistent zoonotic risk: epidemiology and current pharmacological management.Frontiers in pharmacology · 2026Review
- Epidemiological characteristics and spatiotemporal heterogeneity of hemorrhagic fever with renal syndrome in the Jiaodong Peninsula region, China, 2019-2025.Frontiers in public health · 2026Article
- Orthohantavirus rodent hosts and genotypes in Southern South America: A narrative review.PLoS neglected tropical diseases · 2025Review
- Hantaan virus-derived peptides that stabilize HLA-E could abrogate inhibition of CD56dimNKG2A+ NK cells.PLoS pathogens · 2025Article
- Meteorological drivers of hemorrhagic fever with renal syndrome in China's Jiaodong Peninsula: an ecological time-series study from 2020 to 2024.Frontiers in public health · 2025Article
- Dynamic alterations of circulating lymphocytes during the trajectory of Hantaan virus-induced hemorrhagic fever with renal syndrome.Frontiers in immunology · 2025Article
- Plasma thrombomodulin is a valuable biomarker to predict the severity of hemorrhagic fever with renal syndrome caused by the Hantaan virus.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Molecular insight into the neutralization mechanism of human-origin monoclonal antibody AH100 against Hantaan virus.Journal of virology · 2024Article
- Epidemiology of Hemorrhagic Fever with Renal Syndrome and Host Surveillance in Zhejiang Province, China, 1990-2021.Viruses · 2024Article
- Article
- Mathematical Model of the Spread of Hantavirus Infection.Pathogens (Basel, Switzerland) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHantavirus infection is an emerging zoonosis and there are two main clinical presentations, hemorrhagic fever with renal syndrome (HFRS) and Hantavirus pulmonary syndrome (HPS). Although Hantavirus infections have a worldwide distribution with a high mortality rate, a safe and effective vaccine or an antiviral drug against the Hantavirus disease is yet to be available. This review summarizes all the efforts undertaken to develop medical countermeasures in vitro, in vivo, and human clinical trials against Hantavirus infections. RECENT
findingsMultiple antivirals are shown to be effective with limited evidence and recent studies on immunotherapy were not very conclusive. There are multiple vaccine candidates with evidence of conferring long protective immunity against Hantaviruses. Some of these had been already trialed on humans. SUMMARY: At present, severe HPS or HFRS case management is purely based on supportive treatments, often in an intensive care unit. Rodent control and public health education and promotion play a major role in preventing Hantavirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.